

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Health Technology Appraisal

Review Proposal of NICE Technology Appraisal Guidance No. 86; on the use of imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Novartis Pharmaceuticals Ltd (imatinib) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Age Concern England • Cancer Black Care • Cancer Equality • Cancer Voices • Cancerbackup • Chinese National Healthy Living Centre • Confederation of Indian Organisations • CORE • Counsel and Care • Equalities National Council • Help the Aged • Macmillan Cancer Relief • Maggie's Centres • Marie Curie Cancer Care • Muslim Council of Great Britain • Muslim Health Network • National Cancer Alliance • National Council for Palliative Care • Rarer Cancers Forum • Sarcoma UK • South Asian Health Foundation • Sue Ryder Care 	<p><u>General</u></p> <ul style="list-style-type: none"> • Age Concern Cymru • Board of Community Health Councils in Wales • British National Formulary • Cancer Care Cymru • Department of Health, Social Services and Public Safety for Northern Ireland • Medicines and Healthcare products Regulatory Agency (MHRA) • National Public Health Service for Wales • NHS Confederation • NHS Purchasing and Supply Agency • NHS Quality Improvement Scotland • Scottish Medicines Consortium <p><u>Possible comparator manufacturer(s)</u></p> <ul style="list-style-type: none"> • (none) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Institute of Cancer Research • MRC Clinical Trials Unit, Cancer Division • National Cancer Research Institute • Policy Research Institute on Ageing and Ethnicity

National Institute for Health and Clinical Excellence

Proposal for review of existing guidance 86, the use of imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours.

Issue date: October 2007

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Tenovus Cancer Information Centre <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • Association of Surgeons of Great Britain and Ireland • Association of Upper GI Surgeons • British Association for Services to the Elderly • British Association of Surgical Oncology • British Oncological Association • British Society of Gastroenterology • Cancer Networks Pharmacists Forum • Cancer Research UK • National Association of Primary Care • Pelican Cancer Foundation • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians, Medical Oncology Joint Special Committee • Royal College of Radiologists • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine – Intellectual Disabilities Forum • UK Oncology Nursing Society • United Kingdom Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Cumbria PCT • Department of Health • East Sussex Downs and Weald PCT • Welsh Assembly Government 	<p><u>Assessment Group/Evidence Review Group</u></p> <ul style="list-style-type: none"> • Assessment/Evidence Review Group • National Coordinating Centre for Health Technology Assessment <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Collaborating Centre for Cancer <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • (none)

National Institute for Health and Clinical Excellence

Proposal for review of existing guidance 86, the use of imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours.

Issue date: October 2007

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

National Institute for Health and Clinical Excellence

Proposal for review of existing guidance 86, the use of imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours.

Issue date: October 2007

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment team

An independent academic group (commissioned by the NHS Research and Development Health Technology Assessment Programme [HTA Programme] to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).

National Institute for Health and Clinical Excellence

Proposal for review of existing guidance 86, the use of imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours.

Issue date: October 2007

Manufacturer table

The matrix lists the manufacturers who have been invited to participate in a technology appraisal. As an appraisal progresses the matrix may not necessarily list all the relevant products relating to it (as manufacturers may decide that they do not wish to be involved). This table has been produced to capture all the related products for easy identification of interests for anyone involved in the topic.

<i>Consultees</i>	
Manufacturer	Generic Name
Novartis Pharmaceuticals Ltd	imatinib
<i>Commentators</i>	
Manufacturer	Generic Name
None	

National Institute for Health and Clinical Excellence

Proposal for review of existing guidance 86, the use of imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours.

Issue date: October 2007